MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Yu W, Jiang J, Xie L, et al. Mortality trends in colorectal cancer in China during 2000–2015: a joinpoint regression and age–period cohort analysis. Prev Chronic Dis. 2018;15:E156. doi:10.5888/pcd15.18032930576278
   PubMed Web of Science ®Google Scholar
• Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82:114–129. doi:10.1016/S0025-6196(11)60974-917285793
   PubMed Web of Science ®Google Scholar
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117. doi:10.3322/caac.2122024639052
   PubMed Web of Science ®Google Scholar
• Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122–1143. doi:10.7150/thno.1154326199650
   PubMed Web of Science ®Google Scholar
• Choi E, Hwang KC. MicroRNAs as novel regulators of stem cell fate. World J Stem Cells. 2013;5:172–187. doi:10.4252/wjsc.v5.i4.17224179605
   PubMedGoogle Scholar
• Zhang G, Zhou H, Xiao H, Liu Z, Tian H, Zhou T. MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci. 2014;59:98–107. doi:10.1007/s10620-013-2858-824026406
   PubMed Web of Science ®Google Scholar
• Ling H, Pickard K, Ivan C, et al. The clinical and biological significance of miR-224 expression in colorectal cancer metastasis. Gut. 2016;65(6):977–989. doi:10.1136/gutjnl-2015-30937225804630
   PubMed Web of Science ®Google Scholar
• Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006. doi:10.1101/gr.22910212045153
   PubMed Web of Science ®Google Scholar
• Yu T, Li J, Yan M, et al. MicroRNA-193a-3p and −5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 2015;34(4):413–423. doi:10.1038/onc.2014.46224469061
   PubMed Web of Science ®Google Scholar
• Mamoori A, Wahab R, Islam F, et al. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. Hum Pathol. 2018;71:145–156. doi:10.1016/j.humpath.2017.10.02429104111
   PubMed Web of Science ®Google Scholar
• Yi Y, Chen J, Jiao C, et al. Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis. Oncol Lett. 2016;12(6):4779–4784. doi:10.3892/ol.2016.522928105186
   PubMed Web of Science ®Google Scholar
• Liu YF, Xu X, Xu XL, et al. MicroRNA-193a-3p inhibits cell proliferation in prostate cancer by targeting cyclin D1. Oncol Lett. 2017;14(5):5121–5128.29142597
   PubMed Web of Science ®Google Scholar
• Pu Y, Zhao F, Cai W, Meng X, Li Y, Cai S. MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. Clin Exp Metastasis. 2016;33:359–372. doi:10.1007/s10585-016-9783-026913720
   PubMed Web of Science ®Google Scholar
• Williams M, Kirschner MB, Cheng YY, et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015;6(27):23480–23495. doi:10.18632/oncotarget.434626125439
   PubMedGoogle Scholar
• Pekow J, Meckel K, Dougherty U, et al. miR-193a-3p is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through upregulation of IL17RD. Clin Cancer Res. 2017;23(17):5281–5291. doi:10.1158/1078-0432.CCR-17-017128600480
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takahashi M, Ohnuma S, et al. microRNA-193a-3p is specifically downregulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer. 2017;17(1):723. doi:10.1186/s12885-017-3739-x29115941
   PubMedGoogle Scholar
• Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013;13:280. doi:10.1186/1471-2407-13-28023758639
   PubMed Web of Science ®Google Scholar
• Seviour EG, Sehgal V, Mishra D, et al. Targeting KRas-dependent tumor growth, circulating tumor cells and metas tasis in vivo by clinically significant miR-193a-3p. Oncogene. 2017;36(10):1339–1350. doi:10.1038/onc.2016.30827669434
   PubMed Web of Science ®Google Scholar
• Teng Y, Ren Y, Hu X, et al. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat Commun. 2017;8:14448. doi:10.1038/ncomms1444828211508
   PubMed Web of Science ®Google Scholar
• Lin MS, Duan BS, Hu JF, et al. Decreased expression of miR-193a-3p is associated with poor prognosis in colorectal cancer. Oncol Lett. 2017;14:1061–1067. doi:10.3892/ol.2017.626628693274
   PubMedGoogle Scholar
• Montuori N, Pesapane A, Rossi FW, et al. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Transl Med UniSa. 2016;15(3):15–21.27896223
   PubMedGoogle Scholar
• Brungs D, Chen J, Aghmesheh M, et al. The urokinase plasminogen activation system in gastroesophageal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23099–23109. doi:10.18632/oncotarget.1548528416743
   PubMedGoogle Scholar
• Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;12(8):24. doi:10.3389/fonc.2018.00024
   Web of Science ®Google Scholar
• Mauro CD, Pesapane A, Formisano L, et al. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017;7(1):9388. doi:10.1038/s41598-017-10062-128839232
   PubMedGoogle Scholar
• Moirangthem A, Bondhopadhyay B, Mukherjee M, et al. Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes. Sci Rep. 2016;6:21903. doi:10.1038/srep2190326906973
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Vettori S, Maurer B, et al. Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Ann Rheum Dis. 2016;75:303–310. doi:10.1136/annrheumdis-2014-20532625384965
   PubMed Web of Science ®Google Scholar
• Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20(5):551–566. doi:10.1517/14728222.2016.111326026667094
   PubMed Web of Science ®Google Scholar
• Mekkawy AH, Pourgholami MH, Morris DL. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev. 2014;34(5):918–956.24549574
   PubMed Web of Science ®Google Scholar
• Bellocq JP, Luporsi E, Barriere J, et al. uPA/PAI-1, Oncotype DX, Mammaprint((R)). Prognosis and predictive values for clinical utility in breast cancer management. Ann Pathol. 2014;34(5):349–351. doi:10.1016/j.annpat.2014.04.01025439987
   PubMed Web of Science ®Google Scholar
• Tang J, Wang J, Fan L, et al. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget. 2016;7(17):24050–24062.26992227
   PubMedGoogle Scholar
• Chiang SP, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol. 2016;311(1):C1–C14. doi:10.1152/ajpcell.00238.201527076614
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res. 2011;71(15):5144–5153. doi:10.1158/0008-5472.CAN-11-042521670079
   PubMed Web of Science ®Google Scholar
• Salvi A, Conde I, Abeni E, et al. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162. doi:10.1186/1476-4598-12-16224330766
   PubMed Web of Science ®Google Scholar
• Noh H, Hong S, Dong Z, Pan ZK, Jing Q, Huang S. Impaired MicroRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer. 2011;2(2):140–150.21779487
   PubMedGoogle Scholar
• Pakneshan P, Teˆtu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res. 2004;10(9):3035–3041. doi:10.1158/1078-0432.CCR-04-100215131040
   PubMed Web of Science ®Google Scholar